20 July 2018 - - Tel Aviv, Israel-based cannabinoid-based treatments developer Therapix Biosciences Ltd. (NASDAQ: TRPX) has released positive results in its pre-clinical studies evaluating THX-160, a novel pharmaceutical CB2 Receptor agonist for the treatment of pain, the company said.
This innovative CB2 receptor agonist, which was found to be superior out of two candidates the company had tested, was synthesized by Raphael Mechoulam, Ph.D., Professor of Medicinal Chemistry at the Hebrew University, and a member of the Therapix Scientific advisory board.
In the preclinical studies, THX-160 was well tolerated and did not cause any significant adverse clinical effects. In addition, efficacy studies demonstrated the analgesic superiority of THX-160 over control and were comparable to high-dose morphine analgesic effects and in some instances exerted greater potency. The efficacy and safety of THX-160 was shown for both acute and chronic pain.
Therapix Biosciences is a specialty clinical-stage pharmaceutical company whose focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.
The company is currently engaged in the following drug development programs based on repurposing an FDA-approved cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome, for the treatment of obstructive sleep apnea, and the treatment of pain; THX-130 for the treatment of mild cognitive impairment and traumatic brain injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.